The burgeoning landscape of therapy for obesity and type 2 diabetes is currently witnessing considerable excitement surrounding both retatrutide and tirzepatide. While both represent novel dual GIP and GLP-1 target agonists, significant distinctions in their pharmacological profiles and clinical study results are emerging. Retatrutide, boasting a s

Retaglutide and tirzepatide represent a novel class of medications known as dual GLP-1 and GIP agonists. These agents regulate both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), two hormones that have a crucial role in regulating blood sugar levels. In individuals with type 2 diabetes, these hormones are of